![Michael Wyand](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Michael Wyand
Chief Executive Officer at Oxeia Biopharmaceuticals, Inc.
Michael Wyand active positions
Companies | Position | Start | End |
---|---|---|---|
Oxeia Biopharmaceuticals, Inc.
![]() Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Director/Board Member | 2017-09-05 | - |
Chief Executive Officer | 2017-09-05 | - | |
Onebiopharma, Inc.
![]() Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Director/Board Member | - | - |
Chief Executive Officer | - | - |
Career history of Michael Wyand
Former positions of Michael Wyand
Companies | Position | Start | End |
---|---|---|---|
EPIRUS BIOPHARMACEUTICALS, INC. | Chief Operating Officer | 2016-05-05 | 2016-06-29 |
Chief Tech/Sci/R&D Officer | 2011-12-31 | 2016-05-05 | |
General Counsel | 2011-12-31 | - | |
President | 2016-05-05 | 2016-06-29 | |
Zalicus, Inc.
![]() Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 2014-05-06 | - |
General Counsel | 2014-05-06 | - |
Training of Michael Wyand
Purdue University | Doctorate Degree |
University of Connecticut | Undergraduate Degree |
Statistics
International
United States | 7 |
Operational
Chief Tech/Sci/R&D Officer | 2 |
General Counsel | 2 |
Director/Board Member | 2 |
Sectoral
Health Technology | 4 |
Consumer Services | 3 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
Zalicus, Inc.
![]() Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
Oxeia Biopharmaceuticals, Inc.
![]() Oxeia Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Oxeia Biopharmaceuticals, Inc. is a clinical-stage biotech company, which develops new, innovative therapies for conditions that are defined by deficits in neurocognition from injury, degeneration and aging. Its two indications are for (i) mild traumatic brain injury (?mTB?) known as concussion, and (ii) the cognitive decline, lethargy and ?brain-fog? associated with Covid-19 infection, known as Covid Longhauler syndrome (?Long Covid?). The company was founded in 2014 by Vishal Bansal, Amit Dilip Munshi & Kartik Kiran Shah and is headquartered in Boston, MA. | Health Technology |
Onebiopharma, Inc.
![]() Onebiopharma, Inc. Medical/Nursing ServicesHealth Services Onebiopharma, Inc. provides health care services. The company is headquartered in Boston, MA. | Health Services |
- Stock Market
- Insiders
- Michael Wyand
- Experience